SCHEMBL20101895

SCHEMBL20101895

CC(C)[C@H]1c2ccc(F)cc2CSc2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HSD17B3 P37058 1/20 0.37
GAA P10253 1/20 0.37
AURKA O14965 1/20 0.35
CHEK2 O96017 1/20 0.35
CDK1 P06493 1/20 0.35
PIM1 P11309 1/20 0.35
FGFR1 P11362 1/20 0.35
CDK2 P24941 1/20 0.35
MARK3 P27448 1/20 0.35
CSNK2A1 P68400 1/20 0.35
MARK2 Q7KZI7 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HTR2A P28223 5/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22508372 1.00 ALDH1A1 (0.38) ALDH1A1MAPTHPGDALOX12TDP1
SCHEMBL10443992 1.00 ALDH1A1 (0.38) ALDH1A1MAPTHPGDALOX12TDP1
SCHEMBL22508496 0.90 AURKA (0.38) HSD17B3AURKACHEK2CDK1PIM1
SCHEMBL22508495 0.90 AURKA (0.38) HSD17B3AURKACHEK2CDK1PIM1
SCHEMBL10444154 0.89 ALDH1A1 (0.41) ALDH1A1MAPTHPGDALOX12TDP1
SCHEMBL10444190 0.89 HSD17B3 (0.42) ALDH1A1MAPTHPGDALOX12TDP1
SCHEMBL10444069 0.86 ALDH1A1 (0.41) ALDH1A1MAPTHPGDALOX12TDP1
SCHEMBL22508366 0.84 ALDH1A1 (0.39) ALDH1A1MAPTHPGDALOX12TDP1
SCHEMBL10444499 0.84 MAPT (0.39) ALDH1A1MAPTHPGDALOX12TDP1
SCHEMBL20101878 0.84 ALDH1A1 (0.39) ALDH1A1MAPTHPGDALOX12TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287004-A1 SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF SHIONOGI & CO., LTD. (JP) 2023-09-14 US disclosed
US-20220177487-A1 FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS NIKANG THERAPEUTICS, INC. 2022-06-09 US disclosed
WO-2020205835-A1 FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2020-10-08 WO disclosed
WO-2020205832-A1 FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2020-10-08 WO disclosed
US-10633397-B2 Substituted polycyclic pyridone derivatives and prodrugs thereof SHIONOGI & CO., LTD. (JP) 2020-04-28 US disclosed
US-20180118760-A1 SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF SHIONOGI & CO., LTD. (JP) 2018-05-03 US disclosed
US-20180118760-A1 SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF SHIONOGI & CO., LTD. (JP) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287004-A1 SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF C3AR1, NR4A1, HAVCR2 ALDH1A1 1319/4885MAPT 4872/4885HPGD 2908/4885
US-10633397-B2 Substituted polycyclic pyridone derivatives and prodrugs thereof C3AR1, NR4A1, HAVCR2 ALDH1A1 1319/4885MAPT 4872/4885HPGD 2908/4885
US-20220177487-A1 FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS PDXK, PNPO, CDKN1A ALDH1A1 2966/4885MAPT 3329/4885HPGD 810/4885
US-20180118760-A1 SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF C3AR1, NR4A1, HAVCR2 ALDH1A1 1319/4885MAPT 4872/4885HPGD 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.